Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity

v2.4.0.6
Consolidated Statements of Shareholders' Equity (USD $)
In Thousands, except Share data
Total
Pharmacos Exakta
Fine Tech
OURLab
OPKO Diagnostics acquisition
Farmadiet acquisition
Common Stock
Common Stock
Pharmacos Exakta
Common Stock
Fine Tech
Common Stock
OURLab
Common Stock
OPKO Diagnostics acquisition
Treasury
Treasury
OPKO Diagnostics acquisition
Treasury
Farmadiet acquisition
Additional Paid-In Capital
Additional Paid-In Capital
Pharmacos Exakta
Additional Paid-In Capital
Fine Tech
Additional Paid-In Capital
OURLab
Additional Paid-In Capital
OPKO Diagnostics acquisition
Additional Paid-In Capital
Farmadiet acquisition
Other Comprehensive Income
Accumulated Deficit
Noncontrolling Interest
Series A Preferred Stock
Series A Preferred Stock
Common Stock
Series A Preferred Stock
Additional Paid-In Capital
Series A Preferred Stock
Accumulated Deficit
Series D Preferred Stock
Series D Preferred Stock
Common Stock
Series D Preferred Stock
Additional Paid-In Capital
Beginning balance at Dec. 31, 2009 $ 31,599           $ 2,538         $ (61)     $ 367,028           $ 1,313 $ (339,229)   $ 10            
Beginning balance, shares at Dec. 31, 2009             253,762,552         (45,154)                       1,025,934            
Equity-based compensation expense 6,922                           6,922                              
Exercise of Common Stock options 74           2               72                              
Exercise of Common Stock options, shares             150,231                                              
Preferred Stock dividend                                               (224)     (224)      
Conversion of Preferred Stock                                               (1) 1          
Conversion of Preferred Stock, shares                                               (128,495) 128,495          
Issuance of Common Stock in connection with acquisition   1,999           13               1,986                            
Issuance of Common Stock in connection with acquisitions, shares               1,371,428                                            
Net loss for the year ended December 31, 2010, December 31, 2011 and December 31, 2012 respectively (18,926)                                         (18,926)                
Cumulative translation adjustment net 1,608                                       1,608                  
Ending balance at Dec. 31, 2010 23,052           2,554         (61)     376,008           2,921 (358,379)   9            
Ending balance, shares at Dec. 31, 2010             255,412,706         (45,154)                       897,439            
Equity-based compensation expense 7,155                           7,155                              
Exercise of Common Stock options 984           4               980                              
Exercise of Common Stock options, shares             422,500                                              
Exercise of Common Stock warrants 260           29               231                              
Exercise of Common Stock warrants, shares             2,925,894                                              
Preferred Stock dividend                                               (60)     (60) (4,704)   (4,704)
Conversion of Preferred Stock                                               (3) 3     1,742 10 1,732
Conversion of Preferred Stock, shares                                               (294,680) 294,680       940,141  
Redemption of Series A Preferred Stock (1,507)                                             (6)   (1,501)        
Redemption of Series A Preferred Stock, shares                                               (602,759)            
Issuance of Common Stock, amount 104,828           294               104,534                              
Issuance of Common Stock, shares             29,397,029                                              
Repurchase of Common Stock (7,832)                     (7,832)                                    
Repurchase of Common Stock, shares                       (2,398,740)                                    
Issuance of Common Stock in connection with acquisition     17,717   22,452       36   45   (199)       17,681   22,606                      
Issuance of Common Stock in connection with acquisitions, shares                 3,615,703   4,494,380   (44,583)                                  
Exakta-OPKO purchase price adjustment 92                           92                              
Net loss for the year ended December 31, 2010, December 31, 2011 and December 31, 2012 respectively (1,283)                                         (1,283)                
Other comprehensive loss (2,014)                                       (2,014)                  
Ending balance at Dec. 31, 2011 160,882           2,975         (8,092)     524,814           907 (359,722)                
Ending balance, shares at Dec. 31, 2011             297,503,033         (2,488,477)                                    
Equity-based compensation expense 5,131                           5,131                              
Exercise of Common Stock options 2,234           10               2,224                              
Exercise of Common Stock options, shares (1,019,967)           1,019,967                                              
Exercise of Common Stock warrants 45           1               44                              
Exercise of Common Stock warrants, shares             65,015                                              
Conversion of Preferred Stock, shares                                                       12,336,556    
Issuance of Common Stock, amount (101,250)                                                          
Issuance of Common Stock, shares 27,000,000           1,086,361                                              
Adjustment of common stock, shares             100,000                                              
Adjustment of common stock, value             (1)               1                              
Issuance of Common Stock in connection with acquisition       32,888   805       71       635       32,817   170                    
Issuance of Common Stock in connection with acquisitions, shares                   7,072,748       195,421                                
Net loss for the year ended December 31, 2010, December 31, 2011 and December 31, 2012 respectively (29,048)                                         (29,048)                
Net loss attributable to noncontrolling interests for the year ended December 31, 2012 (492)                                           (492)              
Other comprehensive loss 6,449                                       6,449                  
Ending balance at Dec. 31, 2012 $ 179,386 [1]           $ 3,056         $ (7,457)     $ 565,201           $ 7,356 $ (388,770) $ (492)              
Ending balance, shares at Dec. 31, 2012             305,560,763         (2,293,056)                                    
[1] As of December 31, 2012, total assets include $5.6 million and total liabilities include $5.5 million related to SciGen (I.L.) Ltd, ("SciGen"), a consolidated variable interest entity. SciGen's consolidated assets are owned by SciGen and SciGen's consolidated liabilities are those as to which there is no recourse against us. Refer to Note 3.